TLOG (TetraLogic Pharmaceuticals) Total Payout Ratio: 0.00 (As of Jul. 08, 2026)


What is TetraLogic Pharmaceuticals Total Payout Ratio?

TetraLogic Pharmaceuticals TLOG Total Payout Ratio is 0.00 as of Jul. 08, 2026.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

TetraLogic Pharmaceuticals's current Total Payout Ratio is 0.00.

TetraLogic Pharmaceuticals Total Payout Ratio Related Terms

TetraLogic Pharmaceuticals Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for TetraLogic Pharmaceuticals's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TetraLogic Pharmaceuticals Total Payout Ratio Chart

TetraLogic Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Total Payout Ratio
0.00 0.00 2.46 0.00 0.05

TetraLogic Pharmaceuticals Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TLOG vs ARGSQ, GTHR, SOAN: Total Payout Ratio Comparison

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TetraLogic Pharmaceuticals Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's Total Payout Ratio falls into.


TetraLogic Pharmaceuticals Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

TetraLogic Pharmaceuticals's Total Payout Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (2.584 + 0 + 0) / -49.724
=0.05

TetraLogic Pharmaceuticals's Total Payout Ratio for the quarter that ended in Sep. 2016 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -8.635
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.00 mean?
TetraLogic Pharmaceuticals (TLOG) has a Total Payout Ratio of 0.00 as of Jul. 08, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on TetraLogic Pharmaceuticals and its competitors.
Is TetraLogic Pharmaceuticals' Total Payout Ratio too high?
TetraLogic Pharmaceuticals' current Total Payout Ratio is 0.00.
How does TetraLogic Pharmaceuticals' Total Payout Ratio compare to ARGSQ and GTHR?
TetraLogic Pharmaceuticals' Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on TetraLogic Pharmaceuticals and its competitors. TetraLogic Pharmaceuticals's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TetraLogic Pharmaceuticals stock overvalued right now?
TetraLogic Pharmaceuticals (TLOG) has a current Total Payout Ratio of 0.00. The current Total Payout Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For TetraLogic Pharmaceuticals (TLOG), the current Total Payout Ratio is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TetraLogic Pharmaceuticals Business Description

Address 343 Phoenixville Pike, Malvern, PA, USA, 19355
TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.